Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs BMRN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

BMRN Overall Winner 6-Pillar Tally: SYRE 0 – 6 BMRN Matrix Metrics: SYRE 2 – 8 BMRN

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas BMRN carries 52.3/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs BMRN
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
BMRN NASDAQ Head-to-Head Winner
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
TTM Revenue $3.66B
Forward P/E 9.1x
Beta / 30D Vol 0.28β · 31% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 56.0 Fund 61.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.4 · SMA20: $56.74 · SMA50: $58.69

6-Pillar Scorecard Institutional Category Breakdown (SYRE 0 – 6 BMRN)

Columns: Metric · SYRE · BMRN
1. Valuation Multiples BMRN
Forward P/E N/M 9.1x
Trailing P/E N/M 8.8x
PEG Ratio N/M 0.34x
EV / Revenue N/M 3.9x
2. Growth & Scale BMRN
Revenue Growth (YoY) +0.0% +32.0%
Earnings Growth (YoY) -99.7% -81.3%
TTM Revenue (USD) N/A $3.66B
Market Cap $9.8B $11.0B
3. Profitability & Quality BMRN
Gross Margin N/A 53.2%
Operating Margin 0.0% 16.3%
Net Profit Margin 0.0% -0.5%
Return on Equity (ROE) -35.0% -0.3%
4. Balance Sheet & Cash Flow BMRN
Cash Generation (TTM) N/A $554M
Cash Flow Margin N/A 15.2%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $3.45B Net Debt (0.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 87.9% (10th %ile) 37.4% (17th %ile)
Put/Call OI Skew N/A 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat BMRN
OpEx & R&D Intensity N/A 36.9% of Rev ($1.35B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (2) vs BMRN (8)
Institutional Metric SYRE BMRN Criterion Row Edge
Market Capitalization
Scale
$9.8B $11.0B Larger Scale BMRN
Trailing P/E Ratio
Valuation
N/M 8.8x Lower Multiple BMRN
Forward P/E Ratio
Valuation
N/M 9.1x Lower Multiple BMRN
Revenue Growth (YoY)
Growth
+0.0% +32.0% Higher Growth BMRN
Operating Margin (TTM)
Profitability
0.0% 16.3% Higher Margin BMRN
Net Profit Margin
Profitability
0.0% -0.5% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
-35.0% -0.3% Higher ROE BMRN
52-Week Range Position
Momentum
88% ($22–$111) 42% ($49–$71) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 0.28β · 31% Vol Lower Realized Risk BMRN
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 52.3 / 100 (HOLD) Higher Composite BMRN
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 53.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.34x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) $554M ($3.45B Net Debt (0.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +18.45 pp
SYRE: +25.11% · BMRN: +6.66%
3M Horizon SYRE +5.65 pp
SYRE: -7.29% · BMRN: -12.94%
6M Horizon SYRE +25.23 pp
SYRE: +42.64% · BMRN: +17.41%
1Y Horizon SYRE +334.18 pp
SYRE: +341.74% · BMRN: +7.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs BMRN. Trailing 12-month operating profitability (SYRE 0.0% vs BMRN 16.3%) and valuation multiples (SYRE N/M vs BMRN 9.1x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
BMRN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.66B
Gross Margin53.2%
Op. Margin16.3%
ROE / Fwd P/E-0.3% · 9.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRN CONSOLIDATION
67d in phase · OBV DISTRIBUTION
Current IV 37.4%
IV Percentile 17th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BMRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRN Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.0B market capitalization and 16.3% operating margin.
OpEx & R&D Reinvestment 36.9% of Rev ($1.35B)
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs BMRN Key Questions & Quantitative Answers

As of Nov 16, 2026, BioMarin Pharmaceuticals Inc (BMRN) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas BMRN carries 52.3/100 (HOLD) at $58.32 (9.1x Forward P/E, 16.3% operating margin). Technically, SYRE sits in a Neutral phase (RSI 56.6, UNCLASSIFIED options structure) and BMRN sits in a Neutral phase (RSI 54.4, CONSOLIDATION options structure).

BMRN leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BMRN at +32.0% YoY revenue growth and -81.3% YoY earnings growth on $3.66B TTM revenue (53.2% gross margin, 16.3% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $3.66B for BMRN. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus 36.9% of Rev ($1.35B) (0 disclosures) for BMRN.

BMRN screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BMRN trades at 9.1x Forward P/E, 8.8x Trailing P/E, 0.34x PEG, and 3.9x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus BMRN (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, BMRN carries 37.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.